Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 33Recurrence 8Lymphoma, Large B-Cell, Diffuse 4Immunoglobulin Light-chain Amyloidosis 4Neoplasms, Plasma Cell 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2Sarcoma, Kaposi 1Proteostasis Deficiencies 1Plasmablastic Lymphoma 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Epstein-Barr Virus Infections 1Burkitt Lymphoma 1Amyloidosis 1Acquired Immunodeficiency Syndrome 1

Interventions

daratumumab 2Vincristine 2Prednisone 2Etoposide 2Doxorubicin 2Cyclophosphamide 2prednylidene 1pomalidomide 1deltacortene 1Rituximab 1Dexamethasone 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Plasmablastic Lymphoma × pomalidomide × Clear all
NCT05389423 2026-04-28

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡